---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-040057"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T08:18:42.494439+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Q3 rev $1.2M, net loss $7.1M; OpRegen Phase 2a enrolling

## Summary
- Revenue $1.2M, down 60% YoY from $3.0M; net loss $7.1M ($0.04/sh) vs $6.1M ($0.04/sh) prior year.
- Cash $41.3M, expected to fund operations into Q1 2025.
- OpRegen Phase 2a in GA secondary to AMD enrolling under Genentech; new data showed rapid retinal structural improvements within 3 months in 5 patients.
- On track to submit OPC1 IND amendment in Q4 2023 for spinal cord injury DOSED study.
- Initiated hypoimmune pluripotent cell line development with Eterna Therapeutics; selected B2M deletion, HLA-E insertion, and third undisclosed edit.

## SEC filing metadata
- accession: 0001493152-23-040057
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000149315223040057/0001493152-23-040057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000149315223040057/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-040057
- JSON: https://secwatch.observer/filing/0001493152-23-040057.json
- Plain text: https://secwatch.observer/filing/0001493152-23-040057.txt

## Key facts
- Earnings Releases
  Lineage Cell Therapeutics, Inc. reported the three months ended September 30, 2023 results: revenue $1.2 milli.
  - Period: the three months ended September 30, 2023
  - Revenue: $1.2 milli
  - Result: reported results
  source text: revenue is generated primarily from licensing fees, royalties, collaboration revenues, and research grants. Total revenues for the three months ended September 30, 2023 were $1.2 milli
  evidence_url: https://www.sec.gov/Archives/edgar/data/876343/000149315223040057/0001493152-23-040057-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.